Oliver Zoihsl

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl et al. · The Lancet · 2023 · 192 citations · Full text

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial

Nina Wressnigg, Romana Hochreiter, Oliver Zoihsl et al. · The Lancet Infectious Diseases · 2020 · 98 citations

Vaccination, Vaccine Safety, Vaccinology +7

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults

Robert P. McMahon, Ulrike Fuchs, Martina Schneider et al. · Journal of Travel Medicine · 2023 · 32 citations · Full text

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

Robert P. McMahon, Sebastian Toepfer, Natascha Sattler et al. · The Lancet Infectious Diseases · 2024 · 29 citations

Vaccination, Vaccine Safety, Vaccine Development +7

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Vera Buerger, Sandra Hadl, Martina Schneider et al. · The Lancet Infectious Diseases · 2024 · 28 citations

Vaccination, Vaccine Safety, Vaccine Development +8